Dr. Sean van Diepen, an Associate Professor and Co-Director at the Mazankowski Alberta Heart Institute, shares his expertise on extracorporeal life support in cardiogenic shock. He discusses the evolution of mechanical circulatory support, highlighting findings from the DANGER trial showing a 20% mortality reduction with the Impella device. The ECLS-SHOCK trial raises concerns about complications despite lack of mortality benefit. Van Diepen emphasizes the need for better patient selection and collaborative care in this critical area of cardiac medicine.